Glucose ControlNCT07433049
Impact of Supplementation in Improving Metabolic Health Outcomes (ISMOS) Study
A study testing Multivitamin/mineral study product in people with Glucose Control and Mental Health, run by Institute for Human Development and Potential (IHDP), Singapore at 1 site in Singapore.
Trial summary
This study investigates the role of multivitamin and multimineral (MVM) supplementation in improving metabolic, musculoskeletal, and mental health among midlife Asian women aged 40-60 years, a critical period marked by hormonal and physiological transitions from pre- to post-menopause. Read more about this study
- Who is it for?
- Ages 40 to 60 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- Glucose Control, Mental Health, Musculoskeletal Health
- What is being tested?
- Multivitamin/mineral study product
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 400 participants
- Where
- 1 siteSingapore
- Study dates
- 20 Jan 2026to Jan 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 to 60 years
- Women only
- Healthy volunteers accepted
- Adult
Who may be able to join
- Women aged 40-60 years old
- Chinese, Malay or Indian
- BMI between 23.0-35.0 kg/m2
- Proficient in English language
- Willing to comply with study protocol \& provide informed consent
Who cannot join
- Pregnant or planning a pregnancy
- Diagnosis with Diabetes, Polycystic Ovary Syndrome (PCOS), autoimmune diseases, chronic organ failure, severe heart disease, eating disorders and/or other medical conditions which in the PI's judgment which may affect study outcomes
- Fasting glucose value ≥ 7.0 mmol/L
- Active cancer or treatment of cancer in the last 3 years
- Participating in other nutritional intervention studies
- Taking oral corticosteroids, anti-psychotic and/or weight loss drugs
Show all 10Show fewer
- Having planned hospitalization in the next 12 months
- Planning to have major diet changes in the next 12 months
- Taking a medically prescribed supplement(s) that contains 3 or more of the ingredients of the study product
- Taking a non-prescribed supplement(s) that contains 3 or more of the ingredients of the study product in the last 1 month
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Mya Thway Tint, PhD contact
Singapore1 site, 1 recruiting
- Recruiting
Institute for Human Development and Potential (IHDP)
Singapore, 117597
Jolene Chee, jolene_chee@a-star.edu.sg
About this study
This study investigates the role of multivitamin and multimineral (MVM) supplementation in improving metabolic, musculoskeletal, and mental health among midlife Asian women aged 40-60 years, a critical period marked by hormonal and physiological transitions from pre- to post-menopause. Evidence from the GUSTO cohort in Singapore has shown that higher plasma levels of vitamins B6, B9, B12, and D are associated with better metabolic profiles, insulin sensitivity, and mental wellbeing, while deficiencies are linked to increased metabolic and psychological risks. Given that vitamin insufficiency and central obesity are highly prevalent among Asian women even at lower BMI, this randomized, double-blind, placebo-controlled trial will evaluate whether 12 months of daily MVM supplementation can reduce MetaboAge and improve metabolic, mental, and muscle health outcomes compared with placebo. Findings will inform preventive strategies for extending health span and mitigating chronic disease risks among midlife women in Asia.
Read the detailed description
Vitamins are essential micronutrients that regulate key metabolic pathways involved in energy metabolism, immune function, and neuronal integrity. Adequate vitamin status is critical during midlife (ages 40-60 years), a period marked by hormonal fluctuations and physiological transitions from pre- to peri- and post-menopause. These transitions profoundly affect women's metabolic, musculoskeletal, and mental health trajectories, often predisposing them to metabolic syndrome, insulin resistance, central adiposity, dyslipidaemia, and hypertension. Concurrently, declines in muscle strength, bone mineral density, and mood are frequently observed, heightening the risk of sarcopenia, osteopenia, and depressive symptoms in later life.
Emerging evidence indicates that suboptimal dietary intake or deficiency of vitamins contributes to these adverse outcomes. Vitamin D insufficiency, highly prevalent in Asia, has been linked to metabolic syndrome, insulin resistance, and mood disturbances in postmenopausal women. Similarly, low levels of B-vitamins, vitamin C, vitamin E, and folate have been associated with impaired glucose regulation, higher inflammatory burden, and poorer muscle function. While several studies in Western populations have reported positive correlations between these micronutrients and musculoskeletal or psychological health, corresponding data in Asian women remain limited despite their higher susceptibility to central obesity and metabolic dysfunction at lower BMI thresholds compared to Western populations.
Findings from the Growing Up in Singapore Towards Healthy Outcomes (GUSTO) cohort provide novel insights into the role of vitamin status in Asian women. Plasma concentrations of vitamins B6, B9, B12, and D were associated with favorable metabolic profiles, including lower metabolic syndrome severity, improved insulin sensitivity, reduced HbA1c, and higher HDL-cholesterol. Furthermore, higher thiamine monophosphate (vitamin B1) levels correlated with greater handgrip strength, while elevated folate was inversely related to depressive symptoms and perceived stress. Importantly, these associations were more pronounced among women with a BMI ≥ 23 kg/m², emphasizing the compounded metabolic vulnerability of overweight Asian phenotypes. Collectively, these findings highlight the potential of multivitamin/multimineral (MVM) supplementation as a preventive strategy to mitigate age-related metabolic, musculoskeletal, and psychological decline during midlife.
Building on these observational findings, this randomized, double-blind, placebo-controlled trial aims to determine whether 12 months of daily MVM supplementation can improve metabolic and overall health in relatively healthy middle-aged Asian women. The trial will recruit women aged 40-60 years, a critical window for metabolic and hormonal adaptation, who are at increased risk of vitamin insufficiency, insulin resistance, and low-grade chronic inflammation. Participants will be randomized to receive either a daily MVM supplement or placebo for one year, with comprehensive assessments at baseline, 6 months, and 12 months.
The investigators hypothesize that daily MVM supplementation for 12 months will reduce MetaboAge, a composite biomarker of metabolic aging and enhance metabolic, musculoskeletal, and mental health outcomes in midlife women compared with placebo.
Primary Objective is to examine the effect of 12-month MVM supplementation on MetaboAge among relatively healthy middle-aged Asian women.
Secondary Objectives are to;
- Evaluate the impact of MVM supplementation versus placebo on metabolic markers (fasting glucose, insulin resistance indices, HbA1c, lipid profile, blood pressure); mental health outcomes (depressive symptoms, perceived stress, quality of life); musculoskeletal health (lean mass, fat mass distribution, bone mineral density, and handgrip strength) and circulating micronutrient and inflammatory marker levels.
- To explore how menopausal status, baseline vitamin status, and body composition modify the observed intervention effects.
Scientific and Public Health Significance This trial is among the first in Asia to integrate multivitamin supplementation with multidimensional health outcomes; metabolic, musculoskeletal, and psychological, within the context of midlife transition. Asians are metabolically predisposed to visceral adiposity and insulin resistance even at lower BMI, placing midlife women at particularly high risk for metabolic syndrome and its sequelae. By addressing micronutrient insufficiency through a low-cost, scalable nutritional approach, this study aims to establish evidence for early preventive strategies that can extend functional health span and reduce the burden of chronic diseases among Asian women.
If proven effective, findings from this trial will support the incorporation of multivitamin supplementation or vitamin status screening into midlife health programs and community-based preventive frameworks, aligning with regional and national goals for promoting healthy longevity and metabolic resilience across the lifespan.
- Being tested
- Multivitamin/mineral study product
- Keywords
- Multivitamin and mineral supplementation, Women, Metabolic health, Mental health, Muscle health
- Medical subject headings
- Psychological Well-Being
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Multivitamin/mineral study productDietary supplement
Participants will be randomised into one of the two study treatment arms
| Study group | Role | What they receive |
|---|---|---|
| Multivitamin/mineral (MVM) study product | Experimental | One MVM study product to be taken once a day for 52 weeks Receives: Dietary Supplement: Multivitamin/mineral study product |
| Placebo study product | Placebo comparator | One placebo study product to be taken once a day for 52 weeks Receives: Dietary Supplement: Multivitamin/mineral study product |
What is being measured
The primary outcome is the main question the study is designed to answer.
Changes in MetaboAge
MetaboAge is a composite biomarker of metabolic aging derived from proton nuclear magnetic resonance (^1H-NMR) metabolomics profiling of serum samples. It reflects overall metabolic health and correlates with cardiometabolic risk and insulin sensitivity. The expected outcome is that daily multivitamin/multimineral (MVM) supplementation for 12 months will result in a reduction in MetaboAge compared with placebo, indicating improved metabolic profile and slower metabolic aging. The change in MetaboAge will be calculated as the difference between post-intervention and baseline values. A negative change in MetaboAge represents metabolic rejuvenation or improvement in metabolic health status.
Measured: Changes in MetaboAge over one year, including: Week 0 (Baseline), Week 26 (Midpoint) and Week 52 (Endpoint)
Secondary outcomes (13)
Anthropometric Measurements
Participants will be measured for their height in m and weight in kg. Height and weight will be combined to report BMI in kg/m^2.
Measured: Week 0 (Baseline), Week 26 (Midpoint), Week 52 (Endpoint)
Blood Pressure Measurements
Blood pressure will be measured using an automated blood pressure monitor.
Measured: Week 0 (Baseline), Week 26 (Midpoint), Week 52 (Endpoint)
Body Composition Assessment
Body composition will be assessed using multi-frequency bioelectrical impedance analysis (BIA) with the InBody 970 (InBody Co., Seoul, Korea). Participants will be measured in a standing position using an 8-point tactile electrode system (hands and feet), and impedance will be recorded across multiple frequencies to estimate total and segmental lean mass, fat mass, and body fat percentage.
Measured: Week 0 (Baseline), Week 26 (Midpoint), Week 52 (Endpoint)
36-Item Short Form Survey (SF-36)
Health-related quality of life will be assessed using the 36-Item Short Form Survey (SF-36), a validated instrument measuring eight domains of physical and mental wellbeing: physical functioning, role limitations due to physical health, bodily pain, general health perceptions, vitality, social functioning, role limitations due to emotional problems, and mental health. Each domain score and the overall physical and mental component summary scores will be calculated according to standardized scoring procedures.
The expected outcome is that 12 months of daily multivitamin/multimineral (MVM) supplementation will lead to improvement in SF-36 scores compared with placebo, reflecting better perceived physical and mental wellbeing during the midlife transition. The change from baseline (ΔSF-36) will be computed for total and domain-specific scores, with higher positive values indicating improved quality of life.
Measured: Week 0 (Baseline), Week 26 (Midpoint), Week 52 (Endpoint)
Menopausal Status
Menopausal Rating Scale (MRS)
Measured: Week 0 (Baseline), Week 26 (Midpoint), Week 52 (Endpoint)
Anxiety
State-Trait Anxiety Inventory (STAI)
Measured: Week 0 (Baseline), Week 26 (Midpoint), Week 52 (Endpoint)
Depression
Beck Depression Inventory (BDI)
Measured: Week 0 (Baseline), Week 26 (Midpoint), Week 52 (Endpoint)
Stress
Perceived Stress Scale (PSS)
Measured: Week 0 (Baseline), Week 26 (Midpoint), Week 52 (Endpoint)
Sleep Quality
Pittsburgh Sleep Quality Index (PSQI)
Measured: Week 0 (Baseline), Week 26 (Midpoint), Week 52 (Endpoint)
Physical Activity
International Physical Activity Questionnaire (IPAQ)
Measured: Week 0 (Baseline), Week 26 (Midpoint), Week 52 (Endpoint)
Dietary Intake
Food Frequency Questionnaire (FFQ)
Measured: Week 0 (Baseline), Week 52 (Endpoint)
Musculoskeletal assessment by peripheral quantitative CT (pQCT)
Bone mineral density and muscle quality of lower limb (Tibia) will be measured using pQCT and measurement of the non-dominant tibia will be performed using Stratec XCT-3000. Single axial scans will be acquired at 4% and 66% of tibial length, expressed as a percentage from the distal reference line, to assess bone and lower-limb muscle.
Bone parameters are derived using manufacturer software with standard contouring and density thresholds to segment total and trabecular compartments at 4% and cortical bone at 66%, generating measures such as total/trabecular volumetric BMD (vBMD), cortical vBMD, cortical thickness, cross-sectional area, and strength indices. At the 66% site, soft-tissue segmentation is additionally performed to quantify calf muscle cross-sectional area (CSA), muscle density, and subcutaneous/intermuscular fat CSA, using predefined attenuation thresholds to separate muscle from adipose tissue.
Measured: From enrollment to the end of 12 months multi-vitamin supplementation.
Physical performance assessment
Physical performance will be assessed using a standardized physical performance battery that includes tests of handgrip strength, gait speed (4-meter walk test), chair stand test, and balance test. Composite physical performance scores will be derived according to established protocols, with higher scores reflecting better functional capacity and musculoskeletal health.
The expected outcome is that 12 months of daily multivitamin/multimineral (MVM) supplementation will lead to improvements or maintenance of physical performance scores compared with placebo, indicating enhanced muscle strength, endurance, and coordination during the midlife transition. The change from baseline will be calculated for each test and the composite score, with positive values representing improved physical function.
Measured: From enrollment to end of 12 months multi-vitamin supplementation
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Feb 2026
- Study start20 Jan 2026
- Primary completionJan 2028 (estimated)
- Study completionJan 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Glucose ControlStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- A single center, prospective, double-blind, placebo-controlled Randomised Control Trial. Eligible women will be randomised at baseline to either intervention or control group. Participants will receive the assigned intervention from baseline to week 52.
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 400 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Institute for Human Development and Potential (IHDP), Singapore
- Sponsor type
- University, hospital or other
- Collaborators
- HALEON
- Responsible party
- Principal investigator, Johan Eriksson, Institute for Human Development and Potential (IHDP), Singapore
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07433049
- Sponsor's protocol ID
- 2025-064
- Status last verified
- Feb 2026
- First submitted
- 22 Dec 2025
- Last updated
- 25 Feb 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 25 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Impact of Supplementation in Improving Metabolic Health Outcomes (ISMOS) Study
- ClinicalTrials.gov ID
- NCT07433049
- Acronym / sponsor ID
- 2025-064
- Keywords
- Multivitamin and mineral supplementation, Women, Metabolic health, Mental health, Muscle health
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 400 participants (estimated)
- Lead sponsor
- Institute for Human Development and Potential (IHDP), SingaporeUniversity, hospital or other
- Collaborators
- HALEON
- Study start
- 20 Jan 2026 (actual)
- Primary completion
- Jan 2028 (estimated)
- Study completion
- Jan 2028 (estimated)
- First posted
- 25 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study investigates the role of multivitamin and multimineral (MVM) supplementation in improving metabolic, musculoskeletal, and mental health among midlife Asian women aged 40-60 years, a critical period marked by hormonal and physiological transitions from pre- to post-menopause. Evidence from the GUSTO cohort in Singapore has shown that higher plasma levels of vitamins B6, B9, B12, and D are associated with better metabolic profiles, insulin sensitivity, and mental wellbeing, while deficiencies are linked to increased metabolic and psychological risks. Given that vitamin insufficiency and central obesity are highly prevalent among Asian women even at lower BMI, this randomized, double-blind, placebo-controlled trial will evaluate whether 12 months of daily MVM supplementation can reduce MetaboAge and improve metabolic, mental, and muscle health outcomes compared with placebo. Findings will inform preventive strategies for extending health span and mitigating chronic disease risks among midlife women in Asia.
Detailed description
Vitamins are essential micronutrients that regulate key metabolic pathways involved in energy metabolism, immune function, and neuronal integrity. Adequate vitamin status is critical during midlife (ages 40-60 years), a period marked by hormonal fluctuations and physiological transitions from pre- to peri- and post-menopause. These transitions profoundly affect women's metabolic, musculoskeletal, and mental health trajectories, often predisposing them to metabolic syndrome, insulin resistance, central adiposity, dyslipidaemia, and hypertension. Concurrently, declines in muscle strength, bone mineral density, and mood are frequently observed, heightening the risk of sarcopenia, osteopenia, and depressive symptoms in later life.
Emerging evidence indicates that suboptimal dietary intake or deficiency of vitamins contributes to these adverse outcomes. Vitamin D insufficiency, highly prevalent in Asia, has been linked to metabolic syndrome, insulin resistance, and mood disturbances in postmenopausal women. Similarly, low levels of B-vitamins, vitamin C, vitamin E, and folate have been associated with impaired glucose regulation, higher inflammatory burden, and poorer muscle function. While several studies in Western populations have reported positive correlations between these micronutrients and musculoskeletal or psychological health, corresponding data in Asian women remain limited despite their higher susceptibility to central obesity and metabolic dysfunction at lower BMI thresholds compared to Western populations.
Findings from the Growing Up in Singapore Towards Healthy Outcomes (GUSTO) cohort provide novel insights into the role of vitamin status in Asian women. Plasma concentrations of vitamins B6, B9, B12, and D were associated with favorable metabolic profiles, including lower metabolic syndrome severity, improved insulin sensitivity, reduced HbA1c, and higher HDL-cholesterol. Furthermore, higher thiamine monophosphate (vitamin B1) levels correlated with greater handgrip strength, while elevated folate was inversely related to depressive symptoms and perceived stress. Importantly, these associations were more pronounced among women with a BMI ≥ 23 kg/m², emphasizing the compounded metabolic vulnerability of overweight Asian phenotypes. Collectively, these findings highlight the potential of multivitamin/multimineral (MVM) supplementation as a preventive strategy to mitigate age-related metabolic, musculoskeletal, and psychological decline during midlife.
Building on these observational findings, this randomized, double-blind, placebo-controlled trial aims to determine whether 12 months of daily MVM supplementation can improve metabolic and overall health in relatively healthy middle-aged Asian women. The trial will recruit women aged 40-60 years, a critical window for metabolic and hormonal adaptation, who are at increased risk of vitamin insufficiency, insulin resistance, and low-grade chronic inflammation. Participants will be randomized to receive either a daily MVM supplement or placebo for one year, with comprehensive assessments at baseline, 6 months, and 12 months.
The investigators hypothesize that daily MVM supplementation for 12 months will reduce MetaboAge, a composite biomarker of metabolic aging and enhance metabolic, musculoskeletal, and mental health outcomes in midlife women compared with placebo.
Primary Objective is to examine the effect of 12-month MVM supplementation on MetaboAge among relatively healthy middle-aged Asian women.
Secondary Objectives are to;
- Evaluate the impact of MVM supplementation versus placebo on metabolic markers (fasting glucose, insulin resistance indices, HbA1c, lipid profile, blood pressure); mental health outcomes (depressive symptoms, perceived stress, quality of life); musculoskeletal health (lean mass, fat mass distribution, bone mineral density, and handgrip strength) and circulating micronutrient and inflammatory marker levels.
- To explore how menopausal status, baseline vitamin status, and body composition modify the observed intervention effects.
Scientific and Public Health Significance This trial is among the first in Asia to integrate multivitamin supplementation with multidimensional health outcomes; metabolic, musculoskeletal, and psychological, within the context of midlife transition. Asians are metabolically predisposed to visceral adiposity and insulin resistance even at lower BMI, placing midlife women at particularly high risk for metabolic syndrome and its sequelae. By addressing micronutrient insufficiency through a low-cost, scalable nutritional approach, this study aims to establish evidence for early preventive strategies that can extend functional health span and reduce the burden of chronic diseases among Asian women.
If proven effective, findings from this trial will support the incorporation of multivitamin supplementation or vitamin status screening into midlife health programs and community-based preventive frameworks, aligning with regional and national goals for promoting healthy longevity and metabolic resilience across the lifespan.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
- Model description
- A single center, prospective, double-blind, placebo-controlled Randomised Control Trial. Eligible women will be randomised at baseline to either intervention or control group. Participants will receive the assigned intervention from baseline to week 52.
| Arm | Type | Receives |
|---|---|---|
| Multivitamin/mineral (MVM) study product | Experimental | Dietary Supplement: Multivitamin/mineral study productOne MVM study product to be taken once a day for 52 weeks |
| Placebo study product | Placebo comparator | Dietary Supplement: Multivitamin/mineral study productOne placebo study product to be taken once a day for 52 weeks |
Who may qualify
- Ages
- 40 to 60 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (5 listed)
- Women aged 40-60 years old
- Chinese, Malay or Indian
- BMI between 23.0-35.0 kg/m2
- Proficient in English language
- Willing to comply with study protocol \& provide informed consent
Key exclusion criteria (10 listed)
- Pregnant or planning a pregnancy
- Diagnosis with Diabetes, Polycystic Ovary Syndrome (PCOS), autoimmune diseases, chronic organ failure, severe heart disease, eating disorders and/or other medical conditions which in the PI's judgment which may affect study outcomes
- Fasting glucose value ≥ 7.0 mmol/L
- Active cancer or treatment of cancer in the last 3 years
- Participating in other nutritional intervention studies
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Multivitamin/mineral study productParticipants will be randomised into one of the two study treatment arms | Dietary supplement | Multivitamin/mineral (MVM) study product, Placebo study product |
Primary outcome
Changes in MetaboAge
Time frame: Changes in MetaboAge over one year, including: Week 0 (Baseline), Week 26 (Midpoint) and Week 52 (Endpoint)
MetaboAge is a composite biomarker of metabolic aging derived from proton nuclear magnetic resonance (^1H-NMR) metabolomics profiling of serum samples. It reflects overall metabolic health and correlates with cardiometabolic risk and insulin sensitivity. The expected outcome is that daily multivitamin/multimineral (MVM) supplementation for 12 months will result in a reduction in MetaboAge compared with placebo, indicating improved metabolic profile and slower metabolic aging. The change in MetaboAge will be calculated as the difference between post-intervention and baseline values. A negative change in MetaboAge represents metabolic rejuvenation or improvement in metabolic health status.
13 secondary outcomes
Anthropometric Measurements
Time frame: Week 0 (Baseline), Week 26 (Midpoint), Week 52 (Endpoint)
Blood Pressure Measurements
Time frame: Week 0 (Baseline), Week 26 (Midpoint), Week 52 (Endpoint)
Body Composition Assessment
Time frame: Week 0 (Baseline), Week 26 (Midpoint), Week 52 (Endpoint)
36-Item Short Form Survey (SF-36)
Time frame: Week 0 (Baseline), Week 26 (Midpoint), Week 52 (Endpoint)
Menopausal Status
Time frame: Week 0 (Baseline), Week 26 (Midpoint), Week 52 (Endpoint)
Anxiety
Time frame: Week 0 (Baseline), Week 26 (Midpoint), Week 52 (Endpoint)
Depression
Time frame: Week 0 (Baseline), Week 26 (Midpoint), Week 52 (Endpoint)
Stress
Time frame: Week 0 (Baseline), Week 26 (Midpoint), Week 52 (Endpoint)
Sleep Quality
Time frame: Week 0 (Baseline), Week 26 (Midpoint), Week 52 (Endpoint)
Physical Activity
Time frame: Week 0 (Baseline), Week 26 (Midpoint), Week 52 (Endpoint)
Dietary Intake
Time frame: Week 0 (Baseline), Week 52 (Endpoint)
Musculoskeletal assessment by peripheral quantitative CT (pQCT)
Time frame: From enrollment to the end of 12 months multi-vitamin supplementation.
Physical performance assessment
Time frame: From enrollment to end of 12 months multi-vitamin supplementation
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Feb 2026.
- Individual participant dataSharing planned: No
Related trials for Glucose Control
Not yet recruitingPhase 3
Efficacy and Safety of Once-Weekly SHR-3167 Compared With Once-Daily Insulin Glargine in Adults With Insulin-Naive Type 2 Diabetes
Type 2 Diabetes
Not yet recruitingPhase 3
A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These Participants May or May Not Also Have Type 2 Diabetes
Obesity, Overweight
Not yet recruiting
Impact of Endoscopic Sleeve Gastroplasty (ESG) in Obese Adults With Type 2 Diabetes (T2D)
Type 2 Diabetes Mellitus (T2D), Obesity (BMI>30)
Active, not recruiting
SweetSpot - The Effect of Non-nutritive Sweeteners on Health
Healthy Adult
Not yet recruitingPhase 2
Osilodrostat for Glycemic Control in Mild Autonomous Cortisol Secretion (MACS) With Difficult-To-Control Type 2 Diabetes - A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study
Mild Autonomous Cortisol Secretion (MACS), Diabetes Mellitus (Type 2)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Mya Thway Tint, PhD contact
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Multivitamin/mineral study product in people with Glucose Control and Mental Health, run by Institute for Human Development and Potential (IHDP), Singapore at 1 site in Singapore.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 25 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Singapore. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Johan Eriksson, MD (80616604, johan_eriksson@a-star.edu.sg), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Changes in MetaboAge (time frame: Changes in MetaboAge over one year, including: Week 0 (Baseline), Week 26 (Midpoint) and Week 52 (Endpoint)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Feb 2026.